title: 8-Methoxypsoralen-DNA adducts in patients treated with 8-methoxypsoralen and ultraviolet A light.
abstract: The combination of 8-methoxypsoralen (8-MOP) plus ultraviolet A light (320-400 nm), termed PUVA, is used in the treatment of psoriasis, a hyperproliferative disease of the skin. This treatment results in the formation of specific 8-MOP adducts with cellular DNA. We have previously developed monoclonal antibodies which recognize these 8-MOP photoadducts. We now report the use of these antibodies in an indirect immunofluorescence technique to study human skin biopsies. Nuclei in 3 of 5 skin biopsies from psoriasis patients undergoing PUVA therapy were positive for adducts. The presence of adducts by immunofluorescence did not correlate with plasma levels of 8-MOP. Enzyme-linked immunosorbent assays, used to determine whether 8-MOP photoadducts could be detected in DNA isolated from the lymphocytes of psoriasis patients after PUVA therapy, were negative.
authors.affiliation: Comprehensive Cancer Center, Columbia University, New York 10032.
authors.forename: X Y
authors.initials: XY
authors.lastname: Yang
authors.forename: F P
authors.initials: FP
authors.lastname: Gasparro
authors.forename: V A
authors.initials: VA
authors.lastname: DeLeo
authors.forename: R M
authors.initials: RM
authors.lastname: Santella
mesh_terms: D000911:Antibodies, Monoclonal; D001706:Biopsy; D002851:Chromatography, High Pressure Liquid; D004249:DNA Damage; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D006801:Humans; D008730:Methoxsalen / Q000378:metabolism*; D011701:PUVA Therapy / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D012867:Skin / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D008730:Methoxsalen